Re-Purposing FDA-Approved Drugs for Opioid Use Disorder

Krishna Patel, David Waldron, Nicholas Graziane

Research output: Contribution to journalArticlepeer-review


Objective: To investigate FDA-approved drugs prescribed for unrelated diseases or conditions that promote remission in subjects diagnosed with opioid use disorder (OUD). Methods: This was a retrospective observational study utilizing the TriNetX electronic medical record data. Subjects between 18 and 65 years old were included in this study. First, a drug screen was employed to identify medications used for chronic illness that are associated with OUD remission. Based on Fisher’s exact test for significance, 28 of 101 medications were selected for further analysis. Positive (buprenorphine/methadone) and negative controls (benazepril) were included in the analysis. Medications were analyzed in the absence and presence of buprenorphine or methadone, two medications used to treat OUD, to identify the likelihood of OUD remission up to one year following the index event. Results: We identify 8 medications (prazosin, propranolol, lithium carbonate, olanzapine, quetiapine, bupropion, citalopram, and escitalopram) that may be useful for increasing remission in OUD in the absence of buprenorphine or methadone. Additionally, our results identify psychiatric medications that when taken alongside buprenorphine and methadone improve remission rates. Conclusion: These results provide medication options that may be useful in treating OUD as well as integrated therapies to treat comorbid mental illness.

Original languageEnglish (US)
Pages (from-to)1751-1760
Number of pages10
JournalSubstance Use and Misuse
Issue number13
StatePublished - 2023

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Health(social science)
  • Public Health, Environmental and Occupational Health
  • Psychiatry and Mental health

Cite this